|
European Journal of General Medicine
Medical Investigations Society
ISSN: 1304-3897
Vol. 1, Num. 2, 2004, pp. 48-51
|
European Journal of General Medicine, Vol. 1, No. 2, 2004, pp. 48-51
CASE REPORT
THYROTOXIC PERIODIC PARALYSIS - a case report and review of the literature
Mustafa Aldemir1, Cahfer Güloğlu2,
Ozan Balakan3, Ali Süner3,
Ziya Kaya4
Dicle University, Faculty of Medicine, Departments of General Surgery1,
Emergency Medicine2, Internal Medicine3,
Anaesthesiology and Reanimation4
Correspondence: Mustafa ALDEMİR, MD, Dicle Üniversitesi,
Tıp Fakültesi, İlk ve Acil Yardım AD. 21280, Diyarbakır,
Turkey. Tel: +90 412 248 8155. Fax: +90 412 248 8440. Email: maldemir21@hotmail.com
Thyrotoxic periodic paralysis (TPP) is an uncommon disorder characterized by
simultaneous thyrotoxicosis, hypokalaemia, and paralysis and is the most
common acquired form of periodic paralysis. It is usually associated
with low plasma potassium levels and is often precipitated by physical
activity or ingestion of carbohydrates. We presented a 35-year-old man
with hyperthyroidism who admitted applied to the emergency department
with an episode of flaccid quadriparalysis following oral diclophenac
sodium usage for lumbar disk hernia and the review of the literature
on this subject. Physical and laboratory examination revealed sinus tachycardia,
diffuse toxic goiter, flaccid quadriparalysis, a low serum potassium
level (1.51 mmol/L), ST segment depression, coincidental horseshoe kidney.
Potassium chloride was admitted via both parenteral and orally. Meanwhile
antithyroid treatment (propylthiouracil and propranolol) was also given.
Early diagnosis is important for planning antithyroid treatment, protecting
the patient from further episodes of paralysis and avoidance of precipitating
factors. In our patient, electrolyte imbalance appeared secondary to
polyuria and vomiting, serious pain and physical stress may have triggered
TTP.
Key words: Thyrotoxic periodic paralysis, hypokalaemia, precipitating
factors.
INTRODUCTION
Thyrotoxic periodic paralysis is an uncommon disorder characterized by simultaneous
thyrotoxicosis, hypokalaemia, and paralysis and is the most common acquired
form of periodic paralysis (1,2). 90% of all cases reported in the literature
were constituted by Orientals (3,4). It has also been reported in Caucasians
(5), native American Indians (6), Blacks (7) and Aborigines (8). Most
cases are due to familial or primary hypokalaemic periodic paralysis;
sporadic cases are associated with numerous other conditions including
barium poisoning, hyperthyroidism, renal disorders, licorice ingestion,
certain endocrinopathies, fistulas and gastrointestinal potassium losses
(2,9,10).
We presented a 32-year-old man with hyperthyroidism who applied to the emergency
department with an episode of flaccid quadriparalysis following diclophenac
sodium application for lumbar disk hernia and review of the literature
on this subject.
CASE
The 35-year-old man was admitted to the emergency department because of diffuse
weakness, nausea, vomiting and palpitation. At that day he didn’t
eat extraordinary meal and any fluid replacement including glucose hadn’t
been applied to him. The patient had only taken 225 mg diclophenac sodium
(intramuscularly) himself during the last 5 hours for the lumbar disk
hernia without prescription. At night, 30 minutes after the last injection,
he was complained from polyuria and vomiting. Approximately 10 hours
after the diclophenac injection, quadriparalysis had suddenly appeared.
The patient was suffered from lumbar disk hernia for four years and he
had never used diclophenac preparations before. It was learned from his
brief history that, weight loss (about 10 kg), fatigue, diarrhea, heat
intolerance, nervousness, insomnia and palpitation had appeared during
the last year and his two brothers had also goiter. Physical examination
revealed diffuse thyromegaly, mild exophthalmos without lid lag, normal
S1 and S2, absence of deep tendon reflexes in the
upper and lower extremities, 0/5 motor strength in his upper and lower
extremities, common anxiety. Vital signs were as follows: blood pressure;
90/60 mmHg, heart rate; 130/min, respirations; 40/min and body temperature;
37˚C.
Complete blood cell count and electrolyte levels were normal except for a serum
potassium level of 1.51mmol/L (normal, 3.3-5.1mmol/L). In addition, patient
had serum creatine phosphokinase level of 1200 U/L (normal, 0-190 U/L),
serum triiodothyronine (T3) level of 2.33 ng/ml (normal, 0.846-2.02
ng/ml), serum thyroxine (T4) of level 17.78 ng/dl (normal,
5.13-14.06 ng/dl), serum free T3 level of 0.797 ng/dl (0.182-0.462
ng/dl ), serum free T4 level of 5.09 ng/dl (normal, 0.932-1.71
ng/dl), serum thyroid-stimulating hormone (TSH) level of 0.005 µIU/ml
(normal, 0.27-4.2 µIU/ml). Electrocardiogram has showed sinus tachycardia
and ST segment depression (in V1-4). Ultrasonography showed
diffuse goiter and horseshoe kidney. The patient was hospitalized due
to hypokalaemic paralysis and Graves’disease.
The patient has received 106 mEq intravenous (iv) potassium chloride during
first six hours. Then he received oral potassium chloride (80 mEq/day).
Meanwhile propylthiouracil (200 mg/day) and propranolol (40 mg/day) were
given to him. Serial measurements of potassium levels showed a steady
return to normal value (3.55 mmol/L) within 8 hours. The improvement
began 30 minutes after potassium application and the patient’s
muscle strength came back to normal on the fingers of the lower extremity
firstly then on arms and at last on legs. Within 10 hours of admission,
paralysis had completely resolved. Deep tendon reflexes were slowly returned
and complete improvement occurred within 18 hours. After 6 hours of admission,
electrocardiographic data were determined as normal. He was discharged
from the hospital on the 2nd day with normal motor strength
and normal reflexes.
DISCUSSION
TPP is predominantly a disease of males, the male: female ratio being 20:1
(3,8). The usual age of onset of the disorder is similar to that of thyrotoxicosis,
as being most common between second and fourth decades (3). Rarely, there
is family history of TPP (3,6). Our patient was a 35-year-old man and
there wasn’t any family history.
The pathogenesis of TPP is uncertain, although it likely involves defects in
membrane bound ion-transporting proteins, such as sodium, K-adenosine
triphosphatase (11), or ion channel proteins (12). Marlier et al (13)
claimed that the activity of erythrocyte Na-K-ATPase was significantly
decreased before treatment in a patient with TPP. Chan et al (14) have
been determined that patients with TPP have hyperinsulinaemia and this
is accompanied by higher Na+, K(+)-ATPase activity. TPP usually follows
a heavy carbohydrate meal and this has been explained by hyperinsulinaemia
stimulating Na+, K(+)-ATPase activity. Total body potassium stores in
TPP remains adequate, but serum potassium decreases due to potassium
migration into muscle cells which causes the muscles to become electrically
unexcitable (2).
Graves’disease is the most common cause of hyperthyroidism in affected
patients, but any cause of thyrotoxicosis, including administration of
excessive amounts of exogenous thyroid hormone, can trigger attacks of
TPP in susceptible patients (2). TPP has been described in patients with
nonimmunologic thyroid diseases, such as toxic nodular goiter and toxic
adenoma. (1,15-17). Paralytic attacks can be induced by insulin and carbohydrate
administration in hyperthyroid patients with TPP, but not in patients
with TPP who have become euthyroid. After patients with TPP have become
euthyroid and symptom-free, paralytic attacks will recur if patients
relapse into a thyrotoxic state (3). Biering et al (18) reported thyrotoxic
periodic paralysis in two patients with adrenal adenomas and hyperandrogenaemia.
It was reported that diclophenac sodium caused hyperkalaemic quadriparesis
(19), anaphylactic shock (20), severe hepatitis (21) and arterial vasospasm
(22), and was a potent inhibitor of prostaglandin E2 (PG-E2)
and IL-6 (23). In our case, profound hypokalaemia and quadriparalysis
were determined despite known hyperkalaemic effect of diclophenac sodium.
In this case, possibly excessive amounts of thyroid hormone increased
electrolyte permeability of the muscle membrane to electrolytes, with
influx of K into the cell so caused failure in depolarization. Other
causes of hypokalaemia are electrolyte imbalance secondary to polyuria
and vomiting. At the same time, serious pain and stress related to lumbar
disk hernia may have triggered TTP.
Some patients complain muscular weakness, especially proximal muscles of the
lower extremities, while marked and generalized weakness of skeletal
muscles is common with more severe potassium depletion (2,16,17). Attacks
of periodic paralysis occur usually at night. Very severe hypokalaemia
may lead to virtually total paralysis including respiratory, bulbar and
cranial musculature. Sudden deaths from respiratory failure and arrhythmia
have been reported (1,2,9,24,25). On physical examination, in addition
to decreased motor power, the patient may demonstrate decreased or absent
tendon reflexes. The sensations and level of consciousness are generally
unaffected (2). Our patient was conscious, any important respiratory
or cardiac problems haven’t been seen, but deep tendon reflexes
were absent together with quadriparalysis. Both of the problems improved
completely after potassium replacement. In our case, TPP occurred at
night after polyuria, vomiting and serious lumber pain following intake
of a total of 225 mg diclophenac sodium in about 5 hours.
The most frequent electrocardiographic changes were ST segment depression with
T wave flattening, sinus tachycardia, and U waves, which are typical
for hypokalaemia and thyrotoxicosis. In patients with TPP, sinus arrest
and second-degree atrioventricular block (26), ventricular fibrillation
(25), and ventricular tachycardia (27) have been described. Electrocardiogram
of our case showed sinus tachycardia and ST segment depression (V1-4).
Hypophosphatemia and hypomagnesemia during paralysis in patients with
TPP have been previously reported (1,28,29) and may contribute to the
muscle weakness (30) along with hypokalaemia. In our patient, any other
electrolyte imbalance other than profound hypokalaemia was not detected.
Hypokalaemia is considered to be the most consistent electrolyte abnormality
in TPP and a hallmark of the syndrome, along with hyperthyroidism. It
has been demonstrated that hypokalaemia is a result of a K shift into
cells and that it is not caused by total-body K depletion and exact mechanism
is unknown (16,17,31). Correction of the hyperthyroid state is the most
definitive treatment for TPP. Hyperthyroidism was managed first with
a thyroid suppressant (methimazole) and propranolol (1,3,5,32,33).
Potassium administration during an acute attack will shorten the duration of
the episode, and treatment with prednisone, potassium supplementation,
or spironolactone may prevent attacks in some patients (9,32,33). Definitive
treatment of hyperthyroidism was achieved with radioactive iodine. Our
patient received totally 106 mEq potassium chloride and recovered in
about 6 hours after arriving to the hospital. 200 mg/day propylthiouracil
and 40 mg/day propranolol were given orally to our patient.
TPP should be taken into consideration in the differential diagnosis of all
acute episodes of motor paralysis especially in young patients. TPP is
treated by cautious replacement of potassium and achievement of a euthyroid
state. Early diagnosis is important to prevent morbidity and mortality,
early treatment protect the patient from further episodes of paralysis
and avoid from precipitating factors.
REFERENCES
- Manoukian MA, Foote JA, Crapo LM: Clinical and metabolic features of thyrotoxic
periodic paralysis in 24 episodes. Arch Intern Med 1999;159:601-6
- Ahlawat SK, Sachdev A: Hypokalaemic paralysis. Postgrad Med J 1999;75:193-7
- McFadzean AJ, Yeung R: Periodic paralysis complicating thyrotoxicosis in
Chinese. Br Med J 1967;1:451-5
- Bergeron L, Sternbach GL: Thyrotoxic periodic paralysis. Ann Emerg Med 1988;17:843-5
- Kodali VR, Jeffcote B, Clague RB: Thyrotoxic periodic paralysis: a case report
and review of the literature. J Emerg Med 1999;17:43-5
- Conway MJ, Siebel JA, Eaton P: Thyrotoxicosis and periodic paralysis: improvement
with beta blockade. Ann Intern Med 1974;81:332-6
- Kilpatrick RE, Seiler-Smith S, Levine SN: Thyrotoxic hypokalemic periodic
paralysis: report of four cases in black American males. Thyroid 1994;4:441-5
- Ghose R, Quail G, King R, Moloney P: Hypokalaemic paralysis in remote aboriginal
communities. Aust Fam Physician 1996;25:1172-3
- Stedwell RE, Allen KM, Binder LS: Hypokalemic paralyses: a review of the
etiologies, pathophysiology, presentation, and therapy. Am J Emerg Med
1992;10:143-8
- Rowbottom SJ, Ray DC, Brown DT: Hypokalemic paralysis associated with renal
tubular acidosis. Crit Care Med 1987;15:1067-8
- Miller C: Potassium selectivity in proteins: oxygen cage or Pi in the face?
Science 1993;261:1692-3
- Ackerman MJ, Clapham DE: Ion channels: basic science and clinical disease.
N Engl J Med 1997;336:1575-86
- Marlier S, Raccah D, Disdier P, et al: Thyrotoxic periodic paralysis. Discussion
of the role of Na-K-ATPase, apropos of a case. Rev Med Interne 1995;16:209-11
- Chan A, Shinde R, Chow CC, et al: Hyperinsulinaemia and Na+, K(+)-ATPase
activity in thyrotoxic periodic paralysis. Clin Endocrinol (Oxf) 1994;41:213-6
- Ko GT, Chow CC, Yeung VT, et al: Thyrotoxic periodic paralysis in a Chinese
population. QJM.1996;89:463-8
- Ober KP, Hennessy JF: Jodbasedow and thyrotoxic periodic paralysis.Arch
Intern Med 1981;141:1225-7
- Kelley DE, Gharib H, Kennedy FP et al. Thyrotoxic periodic paralysis: report
of 10 cases and review of electromyographic findings. Arch Intern Med
1989;149:2597-2600
- Biering H, Bauditz J, Pirlich M, Lochs H, Gerl H. Manifestation of thyrotoxic
periodic paralysis in two patients with adrenal adenomas and hyperandrogenaemia.
Horm Res 2003;59:301-4
- Patel P, Mandal B, Greenway MW: Hyperkalaemic quadriparesis secondary to
chronic diclofenac treatment. Postgrad Med J 2001;77:50-1
- Hadar A, Holcberg G, Mazor M: Anaphylactic shock after diclofenac sodium.
Harefuah 2000;138:211-2
- Bhogaraju A, Nazeer S, Al-Baghdadi Y, et al: Diclofenac-associated hepatitis.
South Med J 1999;92:711-3
- Kornowski R, Pines A, Levo Y: Ischemic stroke following an intramuscular
injection of diclofenac. Case report. Angiology 1995;46:1145-7
- Henrotin YE, Labasse AH, Simonis PE, et al: Effects of nimesulide and sodium
diclofenac on interleukin-6, interleukin-8, proteoglycans and prostaglandin
E2 production by human articular chondrocytes in vitro. Clin Exp Rheumatol
1999;17:151-60
- Chia BL, Lee KH, Cheah JS: Sino-atrial Wenckebach conduction in thyrotoxic
periodic paralysis: a case report. Int J Cardiol 1995;47:285-9
- Fisher J: Thyrotoxic periodic paralysis with ventricular fibrillation. Arch
Intern Med 1982;142:1362-4
- Ee B, Cheah JS: Electrocardiographic changes in thyrotoxic periodic paralysis.
J Electrocardiol 1979;12:263-79
- Davison ET, Davison MJ: Triiodothyronine (T3) toxicosis with hypokalemic
periodic paralysis and ventricular tachycardia. J Electrocardiol 1995;28:161-4
- Tinker TD, Vannatta JB: Thyrotoxic hypokalemic periodic paralysis: report
of four cases and review of the literature. J Okla State Med Assoc 1987;80:11-15,
76-83
- Saeian K, Heckerling PS: Thyrotoxic periodic paralysis in a Hispanic man.
Arch Intern Med 1988;148:708
- Knochel JP: The pathophysiology and clinical characteristics of severe hypophosphatemia.
Arch Intern Med 1977;137:203-20
- Feely J: Potassium shift in thyrotoxic periodic paralysis. Postgrad Med
J 1981;57:238-9
- Gonzalez-Trevino O, Rosas-Guzman J: Normokalemic thyrotoxic periodic paralysis:
a new therapeutic strategy. Thyroid 1999;9:61-3
- Ober KP: Thyrotoxic periodic paralysis in the United States. Report of 7
cases and review of the literature. Medicine (Baltimore) 1992;71:109-20
Copyright 2004 - Medical Investigations Society
|